Dmitry Gabrilovich

Dmitry Gabrilovich

[[File:|frameless|upright=1]]

Gabrilovich in the lab
Born (1961-05-24) May 24, 1961
Minsk, USSR
Occupation Researcher, professor
Years active 1984present

Dmitry Gabrilovich, M.D., Ph.D., is a researcher and Christopher M. Davis professor at The Wistar Institute in Philadelphia.[1][2] His laboratory at Wistar focuses on methods by which tumors are able to suppress the immune system and how to develop new immune therapies to combat this ability.

The Gabrilovich lab focuses on immature myeloid cell biology and its relation to cancer. These cells have been linked to a number of signaling pathways associated with cancer, including NF-κB, Jak-STAT, Notch, Wnt, and Rb, among others.[3][4] His research has found that tumor cells can go through a mechanism that produces a free radical peroxynitrite, causing them to become resistant to certain types of cancer immunotherapy.[5] His research has also focused on monocytic-myeloid derived suppressor cells and polymorphonuclear-myeloid derived suppressor cells and what impact they might have on cancer therapy, since myeloid derived suppressor cells negatively regulate anti-tumor activity.[6]

Prior to joining The Wistar Institute, Gabrilovich was a senior member at the Moffitt Cancer Center in Tampa.[7]

Select publications

References

  1. "Dmitry I. Gabrilovich, M.D., Ph.D.". The Wistar Institute. Retrieved 17 February 2014.
  2. "Prof Dmitry Gabrilovich". Cancer Vaccine Institute. Retrieved 17 February 2014.
  3. "Dmitry I. Gabrilovich, M.D., Ph.D.". The Wistar Institute. Retrieved 17 February 2014.
  4. "Speaker Biography: Dmitry Gabrilovich". Immunopharmacology. Retrieved 17 February 2014.
  5. "Impediment to some cancer immunotherapy involves the free radical peroxynitrite". Science Daily. Retrieved 17 February 2014.
  6. "Cancer-specific myelopoiesis". Nature Asia. Retrieved 17 February 2014.
  7. "Speaker Biography: Dmitry Gabrilovich". Immunopharmacology. Retrieved 17 February 2014.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.